Skip to main content

Live Halozyme Therapeutics, Inc. Share Price Chart

O 95.29H 95.485L 95.29

Halozyme Therapeutics, Inc. Performance Overview

Days Range
▼
$95.95Low
$97.56High

Markets Today

Previous Close$95.97
Open$95.95
Volume940,644
Day's Range$95.95 - $97.56
52W Range$61.23 - $134.00
Market Cap$10.94 B

Historical Performance

1M Returns-21.80
3M Returns-10.98
6M Returns+39.39
1Y Returns+36.37
5Y Returns+169.63
10Y Returns+657.91

Halozyme Therapeutics, Inc. Fundamentals

Market Cap$10.94 B
Dividend yield0.00
PE Ratio25.88
PEG RatioN/A
Revenue$1.40 B
ROE TTM1.54
EPS TTM$3.93
Quarterly Earnings Growth YOYN/A
PB Ratio97.69
EBITDA$890.64 M
Profit Margin22.69
Market Cap$10.94 B
Dividend yield0.00
PE Ratio25.88
PEG RatioN/A
Revenue$1.40 B
ROE TTM1.54
EPS TTM$3.93
Quarterly Earnings Growth YOYN/A
PB Ratio97.69
EBITDA$890.64 M
Profit Margin22.69

Halozyme Therapeutics, Inc. Profit & Loss

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Total Revenue +$325.72 M$354.26 M$451.77 M$376.71 M$481.00 M$492.97 M
Gross Profit +$279.36 M$299.02 M$373.00 M$297.47 M$401.83 M$410.50 M
Operating Income $202.44 M$217.92 M-$44.19 M$184.52 M$287.65 M$294.97 M
EBITDA $222.94 M$238.34 M$267.38 M$218.25 M$321.62 M$329.17 M
Interest Expense -$4.39 M-$4.30 M-$4.91 M-$5.51 M-$5.59 M-$6.04 M
Depreciation $20.50 M$20.42 M$311.57 M$33.73 M$33.97 M$34.20 M
Income Before Tax $204.94 M$218.96 M-$100.85 M$180.33 M$284.90 M$290.63 M
Income Tax Expense $39.78 M$43.73 M$40.74 M$30.28 M$54.99 M$43.58 M
Net Income +$165.16 M$175.22 M-$141.59 M$150.05 M$229.91 M$247.05 M
Net Profit Margin 50.71%49.46%-31.34%39.83%47.8%50.11%

Halozyme Therapeutics, Inc. Financials Balance Sheet In USD

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Share Capital $118.00 K$118.00 K$118.00 K$118.00 K$114.00 K$114.00 K
Reserve & Surplus $332.63 M$479.89 M$36.69 M$192.13 M$143.43 M-$55.35 M
Non-Current Liabilities $1.59 B$880.09 M$2.30 B$2.09 B$2.09 B$3.05 B
Current Liabilities $134.28 M$837.23 M$177.09 M$363.21 M$344.44 M$476.09 M
Total Liabilities $1.72 B$1.72 B$2.48 B$2.45 B$2.43 B$3.53 B
Fixed Assets $437.83 M$419.96 M$1.06 B$1.03 B$1.01 B$975.22 M
Current Assets $1.12 B$1.33 B$825.21 M$1.00 B$933.02 M$1.85 B
Total Assets $2.05 B$2.22 B$2.53 B$2.67 B$2.58 B$3.47 B

Halozyme Therapeutics, Inc. Cash Flow

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Net Income $165.16 M$175.22 M-$141.59 M$150.05 M$229.91 M$247.05 M
Operating Cash Flow $99.71 M$178.60 M$219.03 M$180.08 M$240.89 M$258.27 M
Investing Cash Flow $84.79 M$201.61 M-$741.79 M-$2.88 M-$62.66 M$20.95 M
Financing Cash Flow -$298.97 M-$22.40 M$239.51 M-$1.61 M-$326.25 M$587.64 M
Change in Cash -$114.47 M$357.80 M-$283.24 M$175.59 M-$148.02 M$866.86 M

Halozyme Therapeutics, Inc. Return Calculator

The Halozyme Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$26,994
Invested Amount$10,000
Est. Returns$16,994
Invest in USA Stock Today

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

FAQs

Halozyme Therapeutics, Inc. (HALO) share price as of November 19, 2026 is $95.91. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Halozyme Therapeutics, Inc. (HALO) Share by opening an international trading account with Angel One.
Purchasing Halozyme Therapeutics, Inc. (HALO) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Halozyme Therapeutics, Inc. (HALO) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Halozyme Therapeutics, Inc. (HALO) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Halozyme Therapeutics, Inc. on November 19, 2026, is $10.94 B.
Halozyme Therapeutics, Inc. operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Halozyme Therapeutics, Inc. (HALO) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.